LUD 00-009: Phase 1study of intensive course immunization with NY-ESO-1 peptides inHLA-A2 positive patients with NY-ESO-1-expressing cancer

Akin Atmaca; Alexander Knuth; Antje Neumann; Armin Bender; Dirk Jauml; ger; Eckhart Weidmann; Elke Jauml; ger; Eric Hoffman; Julia Karbach; Linda Pan; Lloyd J. Old; Melina Biskamp; Sacha Gnjatic; Salah E. Al-Batran

首页> 外文期刊>Cancer immunity >LUD 00-009: Phase 1study of intensive course immunization with NY-ESO-1 peptides inHLA-A2 positive patients with NY-ESO-1-expressing cancer

【24h】

LUD 00-009: Phase 1study of intensive course immunization with NY-ESO-1 peptides inHLA-A2 positive patients with NY-ESO-1-expressing cancer

机译：LUD 00-009：在表达NY-ESO-1的HLA-A2阳性患者中使用NY-ESO-1肽进行强化过程免疫的第一阶段研究

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Cancer immunity》 |2007年第2007期|共页
作者
Akin Atmaca; Alexander Knuth; Antje Neumann; Armin Bender; Dirk Jauml; ger; Eckhart Weidmann; Elke Jauml; ger; Eric Hoffman; Julia Karbach; Linda Pan; Lloyd J. Old; Melina Biskamp; Sacha Gnjatic; Salah E. Al-Batran;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors [J] . Ishihara Mikiya, Tono Yasutaka, Miyahara Yoshihiro, Cancer immunology, immunotherapy : . 2020,第4期

机译：NY-ESO-1蛋白癌疫苗与NY-ESO-1表达难治性固体肿瘤患者的NY-ESO-1蛋白癌疫苗的第一阶段I临床试验
2. Induction of CD8 T-cell responses restricted to multiple HLA class i alleles in a cancer patient by immunization with a 20-mer NY-ESO-1f (NY-ESO-1 91-110) peptide [J] . International Journal of Cancer =: Journal International du Cancer . 2013,第2期

机译：通过用20-mer NY-ESO-1f（NY-ESO-1 91-110）肽免疫在癌症患者中诱导限于多个HLA I类等位基因的CD8 T细胞反应
3. CD8~+ T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients [J] . Sacha Gnjatic, Elke Jaeger, Weisan Chen, Proceedings of the National Academy of Sciences of the United States of America . 2002,第18期

机译：NY-ESO-1肽免疫癌症患者后，CD8〜+ T细胞对显性隐性HLA-A2表位的反应
4. Application of a fluorescent peptide assay to the optimization of peptide generation from patient-derived breast cancer xenografts [C] . Yiling Mi, Petra Erdmann-Gilmore, Rose Connors, ASMS Conference on Mass Spectrometry and Allied Topics . 2015

机译：荧光肽测定在患者源乳腺癌异种移植物中优化肽生成的优化
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. LUD 00-009: Phase 1study of intensive course immunization with NY-ESO-1 peptides inHLA-A2 positive patients with NY-ESO-1-expressing cancer [O] . Armin Bender, Julia Karbach, Antje Neumann, 2007

机译：LUD 00-009：第1阶段NY-ESO-1肽强化过程免疫的研究HLA-A2阳性表达NY-ESO-1的癌症患者
7. LUD00-014: Phase I Study of recombinant vaccinia-NY-ESO-1 (rV-NY-ESO-1) and recombinant fowlpox-NY-ESO-1 (rF-NY-ESO-1) in patients with NY-ESO-1 or LAGE positive cancers [O] . 2004

机译：LUD00-014：NY-ESO-患者中重组牛痘-NY-ESO-1（rV-NY-ESO-1）和重组鸡痘-NY-ESO-1（rF-NY-ESO-1）的I期研究1或LAGE阳性癌症
8. Phase II Study of a HER-2/neu Intracellular Domain Peptide-Based Vaccine Administered to Stage IV HER2 Positive Breast Cancer Patients Receiving Trastuzumab [R] . Disis, M. L. 2010

机译：对接受曲妥珠单抗的IV期HER2阳性乳腺癌患者施用HER-2 / neu胞内域肽基疫苗的II期研究

LUD 00-009: Phase 1study of intensive course immunization with NY-ESO-1 peptides inHLA-A2 positive patients with NY-ESO-1-expressing cancer

著录项

相似文献

相关主题

期刊订阅